PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2022.00192022283497-509Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trialJu Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kimhttp://e-cmh.org/upload/pdf/cmh-2022-0019.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2022.0019, http://e-cmh.org/upload/pdf/cmh-2022-0019.pdf
PLoS ONE10.1371/journal.pone.0012226201058e12226Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease BiomarkerGábor Firneisz, Tímea Varga, Gabriella Lengyel, János Fehér, Dóra Ghyczy, Barna Wichmann, László Selmeci, Zsolt Tulassay, Károly Rácz, Anikó Somogyihttp://dx.plos.org/10.1371/journal.pone.0012226
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy10.2147/dmso.s2622842020Volume 133507-3518<p>Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease</p>Lin Chen, Xiujuan Zhang, Li Zhang, Dongmei Zhenghttps://www.dovepress.com/getfile.php?fileID=62152, https://www.dovepress.com/getfile.php?fileID=62152
International Journal of Molecular Sciences10.3390/ijms1612261562015161229207-29218The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model MiceTakayasu Ideta, Yohei Shirakami, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Hisataka Moriwaki, Masahito Shimizuhttp://www.mdpi.com/1422-0067/16/12/26156/pdf
Metabolism10.1016/j.metabol.2017.04.012201773125-134Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese populationTianpeng Zheng, Bo Chen, Liuxue Yang, Xueping Hu, Xiaoxi Zhang, Hongbo Liu, Linyuan Qinhttps://api.elsevier.com/content/article/PII:S0026049517301269?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0026049517301269?httpAccept=text/plain
International Journal of Experimental Pathology10.1111/j.0959-9673.2006.00465.x20068711-16Mouse models in non-alcoholic fatty liver disease and steatohepatitis researchQuentin M. Anstee, Robert D. Goldinhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.0959-9673.2006.00465.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.0959-9673.2006.00465.x/fullpdf
International Journal of Molecular Sciences10.3390/ijms170303762016173376Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver DiseaseLinda Ban, Nicholas Shackel, Susan McLennanhttp://www.mdpi.com/1422-0067/17/3/376/pdf
Journal of Gastroenterology and Hepatology10.1046/j.1440-1746.17.s1.10.x200217S186-S190Non-alcoholic fatty liver diseasePAUL ANGULO, KEITH D LINDORhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1440-1746.17.s1.10.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1440-1746.17.s1.10.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1440-1746.17.s1.10.x/fullpdf
Journal of Gastroenterology and Hepatology10.1046/j.1440-1746.17.s3.32.x200217S385-S388Treatment of non-alcoholic fatty liver diseaseARUN J SANYALhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1440-1746.17.s3.32.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1440-1746.17.s3.32.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1440-1746.17.s3.32.x/fullpdf
Journal of Diabetes10.1111/j.1753-0407.2012.00204.x201243266-280Non-alcoholic fatty liver diseaseAna C. TUYAMA, Charissa Y. CHANGhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1753-0407.2012.00204.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1753-0407.2012.00204.x/fullpdf